^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR exon 19 deletion

    i
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer (NCT04181060)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    12/28/2020
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • Aybintio (bevacizumab biosimilar) • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Primary Tumor Resection With EGFR TKI for Stage IV NSCLC (NCT05215548)
    Phase 2
    National Taiwan University Hospital
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    09/27/2021
    Primary completion :
    10/01/2026
    Completion :
    10/01/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Gilotrif (afatinib)
    Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON) (NCT06120140)
    Phase 2
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    02/16/2024
    Primary completion :
    11/07/2025
    Completion :
    03/31/2026
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC) • minocycline
    Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (NCT04656652)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/21/2020
    Primary completion :
    05/10/2024
    Completion :
    06/21/2025
    EGFR • PD-L1 • BRAF • ALK • MET • RET • ROS1 • NTRK
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation
    |
    docetaxel • Datroway (datopotamab deruxtecan)
    Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations (AMIGO-1) (NCT05299125)
    Phase 2
    Latin American Cooperative Oncology Group
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    05/24/2023
    Primary completion :
    01/30/2026
    Completion :
    07/31/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) (NCT04487080)
    Phase 3
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    09/30/2020
    Primary completion :
    08/11/2023
    Completion :
    06/29/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer (CHRYSALIS) (NCT02609776)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    05/24/2016
    Primary completion :
    01/31/2024
    Completion :
    06/30/2025
    ALK • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR exon 20 insertion • EGFR wild-type • MET exon 14 mutation • MET expression • EGFR exon 20 mutation • EGFR positive
    |
    carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PALOMA-2) (NCT05498428)
    Phase 2
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    11/11/2022
    Primary completion :
    10/31/2025
    Completion :
    08/05/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib) • amivantamab SC (Ami-LC)
    OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain (NCT06068049)
    Phase N/A
    AstraZeneca
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/28/2023
    Primary completion :
    06/15/2029
    Completion :
    06/15/2029
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (CHRYSALIS-2) (NCT04077463)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/04/2019
    Primary completion :
    02/03/2025
    Completion :
    06/03/2026
    EGFR • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR expression • MET expression • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH) (NCT03778229)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/09/2019
    Primary completion :
    08/23/2024
    Completion :
    05/28/2025
    EGFR • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification • EGFR amplification • MET overexpression
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    Medical Access Program for Patritumab Deruxtecan (NCT06099639)
    Phase N/A
    Daiichi Sankyo
    Available
    Last update posted :
    02/06/2025
    ERBB3
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    patritumab deruxtecan (U3-1402)
    Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) (NCT02193282)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/11/2015
    Primary completion :
    10/10/2026
    Completion :
    10/10/2026
    EGFR • ALK
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement
    |
    erlotinib
    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT01708954)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/13/2013
    Primary completion :
    08/14/2015
    Completion :
    03/07/2025
    HER-2 • KRAS • BRAF • RET
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion
    |
    erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (NCT04310007)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    07/13/2020
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR • PD-L1 • KRAS • BRAF • ALK • ROS1
    |
    KRAS G12C • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • ALK rearrangement • EGFR L861Q • ROS1 positive • KRAS G12 • EGFR exon 20 mutation • MET positive • EGFR negative
    |
    Opdivo (nivolumab) • gemcitabine • docetaxel • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Cyramza (ramucirumab) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • lexatumumab (ETR2-ST01) • liposomal gemcitabine (FF-10832)
    A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care (NCT02279004)
    Phase N/A
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    07/03/2014
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    KRAS • BRAF • NRAS
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • KRAS G12
    Korea Post Marketing Surveillance (PMS) Study of Vizimpro (NCT04721106)
    Phase N/A
    Pfizer
    Enrolling by invitation
    Last update posted :
    02/04/2025
    Initiation :
    03/07/2021
    Primary completion :
    03/01/2026
    Completion :
    03/30/2026
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion
    |
    Vizimpro (dacomitinib)
    Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation (ORBITAL) (NCT04233021)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Completed
    Last update posted :
    02/03/2025
    Initiation :
    07/16/2020
    Primary completion :
    03/15/2023
    Completion :
    12/27/2024
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X
    |
    Tagrisso (osimertinib)
    A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC (CoC) (NCT04606771)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    09/28/2020
    Primary completion :
    12/21/2022
    Completion :
    03/28/2025
    MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification
    |
    Tagrisso (osimertinib) • Orpathys (savolitinib)
    Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery (NCT03433469)
    Phase 2
    University of California, San Francisco
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    07/31/2018
    Primary completion :
    01/31/2023
    Completion :
    10/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    Tagrisso (osimertinib)
    Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) (NCT04585477)
    Phase 2
    Stanford University
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    04/08/2021
    Primary completion :
    12/30/2025
    Completion :
    12/30/2026
    PD-L1 • ALK • ROS1
    |
    PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel
    HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NCT04619004)
    Phase 2
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    12/04/2024
    Initiation :
    02/02/2021
    Primary completion :
    11/21/2022
    Completion :
    01/30/2026
    ALK • ROS1
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • ROS1 fusion
    |
    patritumab deruxtecan (U3-1402)
    U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer (U31402-A-U102) (NCT03260491)
    Phase 1
    Daiichi Sankyo
    Recruiting
    Last update posted :
    11/22/2024
    Initiation :
    10/30/2017
    Primary completion :
    03/31/2026
    Completion :
    12/31/2026
    ALK • ROS1
    |
    EGFR L858R • EGFR exon 19 deletion • ALK fusion • EGFR L861Q • ROS1 fusion • EGFR G719X
    |
    patritumab deruxtecan (U3-1402)
    Osimertinib In EGFR Mutant Lung Cancer (NCT03586453)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    11/19/2024
    Initiation :
    08/13/2018
    Primary completion :
    02/28/2026
    Completion :
    03/01/2027
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer (YL202-INT-101-01) (NCT05653752)
    Phase 1
    MediLink Therapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    11/15/2024
    Initiation :
    12/20/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    EGFR • HER-2
    |
    EGFR mutation • HR positive • HER-2 negative • EGFR L858R • EGFR exon 19 deletion • HR positive + HER-2 negative
    |
    BNT326
    Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC (NCT03769103)
    Phase 2
    British Columbia Cancer Agency
    Active, not recruiting
    Last update posted :
    10/31/2024
    Initiation :
    03/19/2019
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib (NCT02364609)
    Phase 1
    Jonathan Riess
    Completed
    Last update posted :
    10/16/2024
    Initiation :
    09/30/2015
    Primary completion :
    04/26/2018
    Completion :
    05/01/2020
    PD-L1
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q
    |
    Keytruda (pembrolizumab) • erlotinib • Gilotrif (afatinib)
    Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer (NCT03122717)
    Phase 1/2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    09/26/2024
    Initiation :
    05/09/2017
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • gefitinib
    A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05880706)
    Phase 2
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    08/07/2024
    Initiation :
    07/19/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • izalontamab brengitecan (BL-B01D1)
    A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET) (NCT05526755)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    03/06/2023
    Primary completion :
    04/05/2029
    Completion :
    04/05/2029
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Tagrisso (osimertinib)
    Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (UCLA l-08) (NCT04285671)
    Phase 1/2
    Jonsson Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    06/13/2024
    Initiation :
    01/29/2021
    Primary completion :
    12/02/2025
    Completion :
    12/02/2026
    HER-2 • AXL
    |
    EGFR mutation • EGFR L858R • HER-2 expression • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp) • Portrazza (necitumumab)
    A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection (ADAURA2) (NCT05120349)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    02/21/2022
    Primary completion :
    08/02/2027
    Completion :
    11/01/2032
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib)
    Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer (NCI-2019-05913) (NCT04085315)
    Phase 1
    Collin Blakely
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    11/12/2019
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR E709K • EGFR exon 19 insertion • EGFR H835L • EGFR L833V • EGFR V834L
    |
    Tagrisso (osimertinib) • alisertib (MLN8237)
    Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor (NCT02496663)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    05/11/2016
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR exon 20 mutation • EGFR T790M negative
    |
    Tagrisso (osimertinib) • Portrazza (necitumumab)
    Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON) (NCT05261399)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    08/03/2022
    Primary completion :
    06/26/2025
    Completion :
    12/17/2026
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR overexpression • MET overexpression • MET mutation
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed • Orpathys (savolitinib)
    Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer (NCT04479306)
    Phase 1
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    06/04/2024
    Initiation :
    06/18/2020
    Primary completion :
    07/27/2023
    Completion :
    07/27/2023
    EGFR • PD-L1
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR L858R + EGFR exon 21 deletion
    |
    Tagrisso (osimertinib) • sapanisertib (CB-228) • alisertib (MLN8237)
    Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm (NCT05546866)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    02/21/2023
    Primary completion :
    06/30/2029
    Completion :
    06/30/2029
    EGFR
    |
    EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR L861Q • EGFR G719X • EGFR S768I • EGFR exon 20 mutation
    |
    Tagrisso (osimertinib)
    Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer (NCT05954871)
    Phase 1
    Genentech, Inc.
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    01/08/2024
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    KRAS • BRAF • NRAS
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • EGFR positive
    |
    Erbitux (cetuximab) • Tagrisso (osimertinib) • migoprotafib (RLY-1971)
    A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2) (NCT04988295)
    Phase 3
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    05/22/2024
    Initiation :
    11/17/2021
    Primary completion :
    07/10/2023
    Completion :
    12/08/2025
    EGFR
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • carboplatin • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)
    Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). (NCT05219162)
    Phase 4
    AstraZeneca
    Completed
    Last update posted :
    05/21/2024
    Initiation :
    02/25/2022
    Primary completion :
    05/09/2024
    Completion :
    05/09/2024
    EGFR • MET
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET amplification
    |
    Tagrisso (osimertinib)